GP73 inhibition alleviates hepatic fibrosis by suppressing TGF-β/mTOR signaling pathways.

PRC1 promotes MAFLD progression by regulating glycolysis/lactylation axis and forming a positive feedback loop.

Patient characteristics and prognostic importance of dialysis in IE-A nationwide study.

Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography.

The therapeutic role of natural compounds mediated through Nrf2 in metabolic dysfunction-associated steatotic liver disease.

Hepatic GAL1 deficiency alleviates steatosis via WWP2-mediated PARP1 degradation and activation of the SIRT1-CPT1A pathway.

This study investigated the effectiveness of COVID-19 vaccination in decompensated cirrhosis. This study comprised a population-based cohort of 1 583 777 patients with chronic liver disease (CLD), including decompensated cirrhosis, from the National Health Insurance Service data in South Korea. The primary outcome was the risk of COVID-19 within 6 months after vaccination between 26 February 2021 and 31 December 2021. Hospitalisation and all-cause mortality rates were also investigated. Target trial specifications with propensity score matching were used to minimise the bias between the unvaccinated and vaccinated groups. The mean age of patients was 54.2 years, and 54.5% were men. In total, 61 765 patients (3.9%) had decompensated cirrhosis. Compared to the unvaccinated group, the vaccinated group exhibited a lower risk of COVID-19 (hazard ratio [HR] = 0.94; 95% confidence interval [CI] = 0.91-0.97), hospitalisation (HR = 0.86; 95% CI = 0.83-0.89), and all-cause mortality (HR = 0.27; 95% CI = 0.20-0.36) in CLD. However, there was no statistical difference in the clinical outcomes among patients with decompensated cirrhosis with respect to COVID-19 vaccination. The multivariable analysis determined that COVID-19 vaccination reduced all-cause mortality in CLD (HR = 0.39; 95% CI = 0.32-0.49) and decompensated cirrhosis increased all-cause mortality in patients with COVID-19 (HR = 2.94; 95% CI = 2.15-4.02). These results were consistent during the pre-Delta and Delta-variant periods. COVID-19 vaccination reduced the risk of COVID-19, hospitalisation, and mortality in CLD. However, patients with decompensated cirrhosis had a poor prognosis independently of COVID-19 vaccination.

Situational panorama of chronic liver diseases: A single-center experience at a university hospital in northeast Mexico (1995-2019).

Nutrition support of children with chronic liver disease: A rapid review and consensus statements from Australasian society of parenteral and enteral nutrition (AuSPEN) Paediatric liver group.

Liver transplantation (LT) in critically ill patients with chronic liver disease is a high-risk procedure. Recent studies show that the frequency of intensive care unit (ICU) LTs has risen, and outcomes of such transplants have improved significantly. Variation in practices and the impact of center experience with ICU LTs on outcomes is unknown outside of acute liver failure (ALF). This study evaluated the impact of center experience with ICU LT on outcome metrics. Using the United Network for Organ Sharing database, we conducted a retrospective analysis of adult liver transplants performed 2014-2023 in which the patient was in an ICU before transplant, excluding those listed for multiorgan, retransplant, or ALF. Critical care requirements, in-hospital, 1-year, and 3-year mortality, and retransplant were compared by center ICU LT volume quartiles. In total, 9542 ICU LTs were performed across 130 centers (12.8% of total LTs). Over half of U.S. centers performed fewer than 5 ICU LTs per year on average, while the centers in the highest quartile performed nearly two-thirds of all ICU LTs in this period. Utilization of dialysis and of concurrent critical care therapies in ICU LT recipients was higher at high-volume centers ( p <0.05). In-hospital, 1-year, and 3-year mortality for ICU LTs overall were 6.2%, 10.4%, and 23.1%, respectively, with no differences across center volume quartiles (all p >0.05). Adjusting for severity of illness, center volume of ICU LTs in the prior year was associated with a small but significant reduction in 1-year post-ICU LT mortality: aOR 0.96 per 5 ICU LTs ( p <0.001). Expansion of LT for ICU candidates does not appear to threaten center-based metrics and may even offer important benefits to future candidates.

It was hypothesized that high red cell distribution width (RDW) due to anemia and the low platelet count due to cirrhosis studies impacts the RDW to platelet ratio (RPR), which can be used as a predictor of significant fibrosis and cirrhosis. For evaluation of the severity of liver disease Child-Turcotte-Pugh (CTP) score is universally used. To determine the correlation between RPR with CTP severity score in patients of chronic liver disease (CLD), and to evaluate the severity of CLD indirectly with RPR. This is a cross-sectional study of 100 patients diagnosed with CLD, conducted in RIMS Ranchi between February 2021 and July 2022. The categorical data were evaluated by the test of proportion, Chi-square, Fisher's exact test as appropriate. The correlation between RPR and CTP total score and class was analyzed using Pearson correlation in SPSS version 22. The mean RDW-coefficient of variation (measurement of red blood cell volume width deviation), referred to as volume curve width for the study population, was 17.1 ± 3.2, while the median and mode were 16.4. The range is between 12.4 and 30.7. The mean platelet value for the study population was 93,522/μl ± 38,756, while the median was 86,000. Univariate Regression Analysis: RPR with a P = 0.001, β = 7.869, t = 4.729, and r2 = 0.186 depicts that the model explains 18.6% of the variance in the total CTP score. RPR holds the potential for evolving as a novel noninvasive marker for assessing the severity of CLD.

Kumatakenin drives renal and hepatic fibrosis via macrophage-to-myofibroblast transition.

Over the past decade, metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease in Japan, with estimated prevalence rising from 33.7% (2020) to 44.8% (2040), owing to an aging population and lean individuals. In this narrative review, we summarize the epidemiology, pathogenesis, diagnostic strategies, and emerging treatments for MASLD and metabolic dysfunction-associated steatohepatitis (MASH) in Japan, culminating in a proposed ideal patient care pathway tailored to local needs. MASLD pathogenesis involves complex interactions between metabolic dysfunction, inflammation, insulin resistance, and genetic susceptibility. In Japan, a stepwise diagnostic algorithm is endorsed, starting with non-invasive liver disease assessments (NILDA) such as fibrosis-4, followed by imaging-based fibrosis evaluation and selective biopsy. We propose a two-tiered diagnosis combining first-line NILDA (fibrosis-4) with second-line NILDA (e.g., enhanced liver fibrosis, Mac-2 binding protein glycosylation isomer, cytokeratin-18 fragment, andserum type IV collagen 7S) to refine risk stratification, reduce unnecessary referrals, and optimize healthcare resources, with qualifying patients referred to a hepatologist and treatment plans based on imaging-based NILDA or liver biopsy. The management of MASLD/MASH relies on lifestyle modification and pharmacological agents targeting metabolic comorbidities. However, novel anti-fibrotic, anti-inflammatory, and metabolism-targeted therapies are advancing, with future treatment decisions expected to integrate genomic and metabolomic profiling alongside NILDA. The proposed care model is multidisciplinary, engaging physicians, hepatologists, dietitians, psychologists, pharmacists, and hepatitis medical care coordinators to address both hepatic and systemic metabolic care. This evolving paradigm emphasizes proactive, personalized care informed by real-world data and long-term monitoring to improve outcomes and quality of life for patients with MASLD/MASH in Japan.

Role of ferroptosis in liver diseases and its implications for therapeutic strategies.

Necrotizing soft-tissue infections (NSTIs) are rapidly progressive infections often characterized by widespread necrosis, sepsis, and multiple organ failure. As such, it is important to individualize treatment decisions using evidence-based prognostication. We aimed to summarize the prognostic association between patient and disease factors and mortality among adult patients with NSTI. We searched three databases (Medline, Embase, and the Cochrane Central Register of Controlled Trials) from inception to September 29, 2025. We included studies that enrolled adult patients with NSTI and evaluated prognostic factors associated with short-term mortality using adjusted models that account for at least age and comorbidity. We pooled effect estimates using a random-effects model. We assessed risk-of-bias using the Quality in Prognosis Studies tool and assessed certainty of evidence using Grading of Recommendations, Assessment, Development, and Evaluations methodology. We included 41 observational cohort studies involving 168,261 patients. Studies were predominantly retrospective cohorts. Patient factors with a moderate or high certainty of association with increased mortality include older age, chronic liver disease, chronic kidney disease, high Charlson Comorbidity Index, and immunosuppression. Disease factors with a moderate or high certainty of association with increased mortality include hypotension, bacteremia, acute kidney injury, coagulopathy, thrombocytopenia, and shock. Several patient and illness factors demonstrate important association with mortality among patients with NSTI. Clinicians should consider these factors in decisions related to escalation of therapy, and counseling patients and family members on potential outcomes.

Chronic liver disease is a progressive, worldwide health crisis, with its incidence and prevalence increasing annually. It causes progressive liver injury and ultimately fibrosis. Globally, it is responsible for approximately 2 million deaths annually. Despite its growing prevalence, there is currently no approved, highly effective targeted therapy for managing liver dysfunction. Targeting caspase-3 activity may attenuate hepatocellular injury, reduce inflammation and oxidative stress, and thereby improve liver functional integrity. Ten cyclic curcumin analogues (2-11) were synthesized, followed by preliminary screening for caspase-3 inhibitory activity. Their structures were confirmed by spectral and microanalytical data. The most active triazole (4) and sulfonamide (5) analogues were further evaluated in vivo to assess their anti-inflammatory, antioxidant, and caspase-3 inhibitory effects in rat liver tissue. Molecular docking study was performed to confirm caspase -3 regulation. Radiation stability study was held. Results: Analogues 4 and 5 significantly improved biochemical and molecular markers associated with liver dysfunction, including reductions in inflammation, oxidative stress, caspase-3 activity, TNF-α, p53, and Bax levels, alongside modulation of Bcl-2 expression. The triazole analogue 4 and sulfonamide analogue 5 demonstrate promising hepatoprotective activity and may represent stable lead compounds for potential therapeutic management of liver dysfunction.

Spectrum of pathogenic variants in ATP7B gene causing Wilson Disease in Mexican patients.

LINC01184 promotes hepatocellular carcinoma development via the miR-193a-3p/DCAF7 axis.

Miao medicine Jinshanxiaoke granules alleviates MASLD via Ampk/Ppar-α and Pi3k/Akt-mediated restoration of hepatic lipid homeostasis.

Metal-phenolic nanoparticles with ROS/pH dual-responsiveness for liver fibrosis therapy via synergistic microenvironment remodeling and metabolic reprogramming.